Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753688 · ClinicalTrials.gov registry record · Phase 3
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT00753688 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 369 participants.
The verdict
NCT00753688, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
Interventions
- DRUG Placebo
- DRUG PAZOPANIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753688
The ClinicalTrials.gov registry entry for NCT00753688 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00753688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753688 about?
NCT00753688 is a clinical study titled "Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy". A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
What is the current status of trial NCT00753688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2008-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00753688?
The interventions under investigation include: Placebo (DRUG), PAZOPANIB (DRUG).
Who is sponsoring clinical trial NCT00753688?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.